The study was to explore the efficacy and safety of sivelestat (SV) in the treatment of severe acute pancreatitis (SAP) with systemic inflammatory response syndrome (SIRS). A total of 102 SAP patients diagnosed and treated in the Emergency Intensive Care Unit of the First Affiliated Hospital of Zhengzhou University from January 2021 to August 2024 were selected. The changes of disease outcome, hospital stays and mortality were compared between the two groups. A total of 102 patients were recruited to control group (n = 56) or SV group (n = 46) according to whether SV was applied or not. There was no significant difference in baseline data at admission between the two groups. After 1 week of treatment, all the indexes in both groups improved. The duration of ventilator use (p = 0.0400) and ICU stays (p = 0.0495) in SV group was shorter than that in control group, but there was no significant difference in mortality between the two groups. Although SV did not reduce the mortality of patients with SAP, it reduced the length of ventilator use and ICU stay.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695592 | PMC |
| http://dx.doi.org/10.1038/s41598-024-84600-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect and safety of sivelestat on acute severe pancreatitis with systemic inflammatory response syndrome: a retrospective study.
Sci Rep
January 2025
Department of emergency ICU, the first affiliated hospital of Zhengzhou University, Henan, 450052, China.
The study was to explore the efficacy and safety of sivelestat (SV) in the treatment of severe acute pancreatitis (SAP) with systemic inflammatory response syndrome (SIRS). A total of 102 SAP patients diagnosed and treated in the Emergency Intensive Care Unit of the First Affiliated Hospital of Zhengzhou University from January 2021 to August 2024 were selected. The changes of disease outcome, hospital stays and mortality were compared between the two groups.
View Article and Find Full Text PDFClinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of ALI/ARDS patients with COVID-19.
Heliyon
September 2024
Department of Pulmonary and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Article Synopsis
- - Sivelestat, a neutrophil elastase inhibitor, is being studied for its potential to help patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) caused by COVID-19, though its effectiveness is still unclear.
- - In a retrospective study involving over 2,400 COVID-19 patients, 102 received sivelestat while 2,352 were matched controls; outcomes measured included 30-day mortality and changes in oxygen levels and cytokine levels.
- - Results showed that sivelestat significantly reduced the risk of 30-day mortality by about 88% in severe/critical COVID-19 patients and lowered levels of certain inflammatory cytokines, indicating possible pulmonary benefits.
Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects.
Eur J Pharm Sci
April 2024
Department of Pharmacy, Henan Provincial People's Hospital, Zhengzhou, China; Department of Pharmacy, Zhengzhou University People's Hospital, Zhengzhou, China; Department of Pharmacy, People's Hospital of Henan University, Zhengzhou, China. Electronic address:
Background And Objective: Neutrophil elastase has been identified as a potential therapeutic target for acute lung injury or acute respiratory distress syndrome, and Sivelestat is a selective, reversible and competitive neutrophil elastase inhibitor. This study was designed to investigate the safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat in healthy Chinese subjects.
Methods: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation clinical trial was carried out.
[Efficacy and safety of sivelestat sodium in patients with sepsis].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
January 2023
Department of General Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Henan Engineering Research Center for Critical Care Medicine, Zhengzhou 450052, Henan, China. Corresponding author: Sun Tongwen, Email:
Objective: To investigate the efficacy and safety of sivelestat sodium in patients with sepsis.
Methods: The clinical data of 141 adult patients with sepsis admitted to the intensive care unit (ICU) of the First Affiliated Hospital of Zhengzhou University from January 1, 2019 to January 1, 2022 were retrospectively analyzed. The patients were divided into the sivelestat sodium group (n = 70) and the control group (n = 71) according to whether they received sivelestat sodium or not.
Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways.
Biomol Biomed
May 2023
Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Medical University, Haikou, Hainan, China; Emergency Medicine Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit of Island Emergency Medicine, Chinese Academy of Medical Sciences (No. 2019RU013), Hainan Medical University, Haikou, Hainan, China.
Sivelestat sodium (SIV), a neutrophil elastase inhibitor, is mainly used for the clinical treatment of acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). However, studies investigating the effects of SIV treatment of ALI are limited. Therefore, this study investigated the potential molecular mechanism of the protective effects of SIV against ALI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!